Silence Therapeutics plc

Silence Therapeutics plc: Your 2025 Annual Report Snapshot

Silence Therapeutics plc's 2025 annual report offers a crucial look into its progress as a clinical-stage biotechnology company. This summary distills key insights from the year ended December 31, 2025, providing investors with a clear and concise overview.

1. Business Overview: What Silence Therapeutics Does and How It Performed in 2025 Silence Therapeutics is a clinical-stage biotechnology company pioneering the development of novel medicines using RNA interference (RNAi) technology. This innovative approach aims to "silence" specific genes responsible for diseases. In 2025, the company significantly advanced its lead product candidates:

   • SLN360: The company advanced SLN360 into Phase 3 clinical trials for treating high lipoprotein(a) (Lp(a)) levels, a genetic risk factor for cardiovascular disease.
   • SLN124: Silence Therapeutics reported positive Phase 2 data for SLN124, which treats iron overload in patients with myelodysplastic syndromes (MDS) and beta-thalassemia. The company plans to initiate a pivotal study for SLN124 in 2026. As a company without commercial products, Silence Therapeutics continued its heavy investment in research and development. Its performance hinges on clinical trial progress and pipeline advancement. The company relies on third-party organizations for much of its manufacturing, research, and development activities.

2. Financial Performance: Revenue, Profit, and Growth As a clinical-stage biotechnology company, Silence Therapeutics does not yet generate revenue from product sales, resulting in a net loss for 2025.

   • Revenue: Total revenue for 2025 reached $58 million, primarily from collaboration agreements, rising from $48 million in 2024. This total comprised $55 million from strategic partnerships (e.g., AstraZeneca, Hansoh) and $3 million in royalty income.
   • Net Loss: Silence Therapeutics reported a net loss of $110 million in 2025, an increase from $95 million in 2024. This larger loss reflects substantial investment in advancing its clinical pipeline.
   • Research & Development (R&D) Expenses: Research and Development (R&D) expenses reached $80 million in 2025, representing a critical investment in its drug development programs. The company expects continued losses as it funds ongoing clinical trials and expands its pipeline.

3. Management's Discussion and Analysis Highlights: Key Achievements and Challenges in 2025 Management highlighted several key achievements and challenges in 2025:

   • Achievements:
     • Advancing SLN360 into Phase 3 marked a significant milestone for the company.
     • Positive Phase 2 data for SLN124 paved the way for pivotal studies.
     • Maintaining strong strategic collaborations provided critical funding and expertise.
     • Securing a robust cash position provided a financial runway into 2028.
   • Challenges:
     • Ongoing net losses due to the absence of commercial products.
     • The inherent high risk and uncertainty of drug development, with no guarantee of regulatory approval or commercial success for its novel RNAi therapies.
     • Significant reliance on third-party partners for manufacturing and certain R&D activities, which introduces potential operational dependencies.
     • The long, complex, and expensive regulatory approval process for new drugs.

4. Financial Health: Cash, Debt, and Liquidity Silence Therapeutics held a relatively strong cash position for its stage, with $320 million in cash and cash equivalents as of December 31, 2025. The company reported no significant long-term debt, relying instead on equity financing and collaboration revenues. This cash, combined with anticipated collaboration payments, should fund operations into 2028. While this provides a solid financial runway, the company expects to raise additional capital in the future to complete clinical development and prepare for commercialization. Such fundraising could dilute the value of existing shares.

   As a "Non-accelerated filer" and "Smaller reporting company," Silence Therapeutics qualifies for scaled-down disclosure requirements based on its public float and revenue levels. Its public float (market value of shares held by non-affiliates) was approximately $206.2 million as of June 30, 2025.

5. Risk Factors Investors should consider the following key risks:

   • Clinical Development & Regulatory Risk: Most drug candidates fail in clinical trials. There is no guarantee that SLN360, SLN124, or other pipeline assets will successfully complete trials, gain regulatory approval (e.g., from the FDA or EMA), or prove safe and effective. This approval process is lengthy, costly, and highly uncertain.
   • Financial Risk: The company has a history of significant net losses and anticipates they will continue. It will require substantial additional funding, which may not be available on favorable terms or at all, potentially delaying or halting development programs.
   • Commercialization Risk: Even if approved, there is no guarantee that products will gain market acceptance, compete effectively, or generate sufficient revenue to become profitable.
   • Reliance on Third Parties: Dependence on external partners for manufacturing, clinical trials, and certain R&D activities introduces risks related to quality, timelines, and performance, which are beyond the company's direct control.
   • Intellectual Property: The company's success depends on its ability to protect its RNAi technology and product candidates through patents; competitors can challenge or circumvent these.
   • Competition: The RNAi and rare disease therapeutic areas are highly competitive, with established pharmaceutical companies and other biotech firms developing similar or alternative treatments.

6. Competitive Position Silence Therapeutics operates in a highly competitive landscape. It competes with other companies developing RNAi therapeutics (e.g., Alnylam Pharmaceuticals, Ionis Pharmaceuticals) and traditional pharmaceutical companies targeting the same indications (e.g., cardiovascular diseases, hematological disorders). Its success will depend on how well its product candidates differentiate themselves in terms of efficacy, safety, and commercial viability against existing and emerging therapies.

7. Leadership and Strategy Changes The 2025 filing reported no significant changes in the company's executive leadership team or its overarching corporate strategy.

8. Future Outlook and Strategy Silence Therapeutics' core strategy focuses on advancing its clinical pipeline, especially SLN360 and SLN124, through pivotal clinical trials and toward regulatory approval. This includes initiating a pivotal study for SLN124 in 2026. The company also plans to expand its early-stage pipeline through internal research and strategic collaborations. Key to its long-term strategy is preparing for the potential commercialization of its lead assets post-approval and securing additional capital to fund these ambitious goals.

9. Industry and Regulatory Environment Regulatory developments in key markets like the United States, United Kingdom, and European Union significantly impact the company's business. Changes in drug pricing legislation, evolving accelerated approval pathways, and stricter data privacy regulations could affect future product development, approval timelines, and commercial success.